Seizures in patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic cohort (LUMINA LIV)

Annals of the Rheumatic Diseases

Volumn 67, Issue 6, 2008, Pages 829-834

  Andrade, R M ^a   Alarcón, Graciela S ^a,d   Gonzalez L A ^a   Fernandez M ^a   Apte, M ^a   Vila L M ^b   McGwin Jr , G ^a   Reveille, J D ^c  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d 830 Faculty Office Tower ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHOTREXATE;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CHRONOLOGY; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE COURSE; DRUG EXPOSURE; ETHNICITY; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GONADAL DISEASE; GROUPS BY AGE; HEART DISEASE; HISPANIC; HUMAN; INTEGUMENT; KIDNEY DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MORTALITY; MULTIVARIATE ANALYSIS; MUSCULOSKELETAL DISEASE; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RHEUMATOLOGY; SEIZURE; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; UNIVARIATE ANALYSIS; VASCULAR DISEASE;

ADULT; AFRICAN AMERICANS; AGE OF ONSET; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS INDICATORS; HISPANIC AMERICANS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SEIZURES; SOCIOECONOMIC FACTORS;

EID: 45149117700     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.077594     Document Type: Article

References (45)

1. Alarcon GS, McGwin G Jr, Bartolucci AA, Roseman J, Lisse J, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum 2001;44:2797- 806.
2. Moore PM. Neuropsychiatric systemic lupus erythematosus. In: Lahita RG, ed. Systemic lupus erythematosus, 3rd edn. San Diego, CA: Academic Press, 1999:575-601.
3. Russell PW, Haserick JR, Zucker EM. Epilepsy in systemic lupus erythematosus; effect of cortisone and ACTH. AMA Arch Intern Med 1951;88:78-92.
4. Besedovsky H, del Rey A, Sorkin E, Dinarello CA. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986;233:652-54.
5. Greenwood DI, Gitlits VM, Alderuccio F, Sentry JW, Toh BH. Autoantibodies in neuropsychiatric lupus. Autoimmunity 2002;35:79-86.
6. West SG. Systemic lupus erythematosus and the nervous system. In: Wallace DJ, Hahn BH, eds. Dubois lupus erythematosus, 6th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2002:693-738.
7. Alarcon GS, Friedman AW, Straaton KV, Moulds JM, Lisse J, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture. Lupus 1999;8:197-209.
8. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
10. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthris Rheum 1999;42:599-608.
11. US Department of Commerce, Bureau of the Census. Current population reports, Series P-23, No. 28 and Series P-60, No. 68 and subsequent years. Washington, DC: Housing and Household Economic Statistics Division, 1995.
12. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
13. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000;27:373- 76.
14. Aarden LA, De Groot ER, Feltkamp TE. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann NY Acad Sci 1975;254:505-15.
15. Hamilton RG, Harley JB, Bias WB, Roebber M, Reichlin M, Hochberg MC, et al. Two Ro (SS-A) autoantibody responses in systemic lupus erythematosus. Correlation of HLA-DR/DQ specificities with quantitative expression of Ro (SS-A) autoantibody. Arthritis Rheum 1988;31:496-505.
16. Harris EN. Special report. The second international anti-cardiolipin standardization workshop/the Kingston anti-phospholipid antibody study (KAPS) group. Am J Clin Pathol 1990;94:476-84.
17. Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 1993;70:787-93.
18. Fernandez M, Alarcon GS, Calvo-Alen J, Andrade RM, McGwin G Jr, Vila L, et al. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthitis Rheum 2007;57:576-84.
19. Alarcon GS, Roseman JM, McGwin G Jr, Uribe A, Bastian HM, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups: XX. Damage as predictor of further damage. Rheumatology 2004;43:202-5.
20. Mackworth-Young CG, Hughes GR. Epilepsy: an early symptom of systemic lupus erythematosus. J Neurol Neurosurg Psychiatry 1985;48:185.
21. Toubi E, Khamashta MA, Panarra A, Hughes GRV. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 1995;99:397-401.
22. Andrade RM, Alarcon GS. Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. Future Rheumatol 2006;1:225-33.
23. Espinola RG, Pierangeli SS, Gharavi AE, Harris EN, Ghara AE. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002;87:518-22.
24. Fessler BJ, Alarcón GS, McGwin GJr, Roseman JM, Bastian HM, Friedman AW, et al. Systemic lupus erythematosus in a multiethnic group: XVI. Hydroxychloroquine usage is associated with a lower risk of damage accrual. Arthritis Rheum 2005;52:1473-80.
25. Wallace DJ. Antimalarials - the 'real' advance in lupus. Lupus 2001;10:385-7.
26. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991;324:150-4.
27. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006;15:577-83.
28. Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006;15:366-70.
29. Alarcon GS, McGwin G, Jr, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, et al. Effect of hydroxychloroquine in the survival of patients with systemic lupus erythematosus. Data from LUMINA, a multiethnic us cohort (LUMINAL). Ann Rheum Dis 2007;66:1168-72.
30. Swaak AJ, van den Brink HG, Smeenk RJ, Manger K, Kalden JR, Tosi S, et al. Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation. Lupus 2001;10:51-8.
31. Mikdashi J, Krumholz A, Handwerger B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology 2005;64:2102-7.
32. Navarrete MG, Brey RL. Neuropsychiatric systemic lupus erythematosus. Curr Treat Options Neurol 2000;2:473-85.
33. Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine 1976;55:323-38.
34. Appenzeller S, Cendes F, Costallat LT. Epileptic seizures in systemic lupus erythematosus. Neurology 2004;63:1808-12.
35. Gibbs JW III, Husain AM. Epilepsy associated with lupus anticoagulant. Seizure 2002;11:207-9.
36. Verrot D, San-Demarco M, Dravet C, Genton P, Disdier P, Bolla G, et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997;103:33-8.
37. Shrivastava A, Dwivedi S, Aggarwal A, Misra R. Anti-cardiolipin and anti-beta2 glycoprotein I antibodies in Indian patients with systemic lupus erythematosus: association with the presence of seizures. Lupus 2001;10:45-50.
38. Liou HH, Wang CR, Chou HC, Arvanov VL, Chen RC, Chang YC, et al. Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons. Life Sci 1994;54:1119-25.
39. Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999;8:127-33.
40. Christodoulou C, Sangle S, D'Cruz DP. Vasculopathy and arterial stenotic lesions in the antiphospholipid syndrome. Rheumatology (Oxford) 2007;46:907-10.
41. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003;102:2717-23.
42. Danowski A, Kickler TS, Petri M. Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 2006;33:1775-9.
43. Mayes B, Brey R. Evaulation and treatment of seizures in patients with systemic lupus erythematosus. J Clin Rheumatol 1996;2:336-45.
44. Heeschen C, Aicher A, Lehmann R, Fichtischerer S, Vasa M, Urbich C, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003;102:1340-6.
45. Alarcon GS, McGwin G Jr, Bastian HM, Roseman J, Lisse J, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum 2001;45:191-202.